F Bernini, M R Soma, A Corsini, R Paoletti
Index: Am. J. Hypertens. 7(7 Pt 2) , 30S-34S, (1994)
Full Text: HTML
A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesions. This action is independent of either blood pressure reduction or hypercholesterolemia. A major problem encountered from the experimental data are the high doses used, which are several times higher than those used in the treatment of humans. One notable exception to this problem is the second-generation calcium antagonist isradipine, which exerts a direct antiatherosclerotic effect in rabbits at doses similar to those used in the clinic. Thus, this review is a summary of the effects and mechanisms of the antiatherosclerotic activity of isradipine.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Isradipine
CAS:75695-93-1 |
C19H21N3O5 |
Cav1.3 channels control D2-autoreceptor responses via NCS-1 ...
2014-08-01 [Brain 137(Pt 8) , 2287-302, (2014)] |
Analysis of responses to the TRPV4 agonist GSK1016790A in th...
2014-01-01 [Am. J. Physiol. Heart Circ. Physiol. 306(1) , H33-40, (2014)] |
L-type calcium channel blockade alleviates molecular and rev...
2013-01-15 [Behav. Brain Res. 237 , 190-9, (2013)] |
Felodipine and isradipine: new calcium-channel-blocking agen...
1993-04-01 [Clin. Pharm. 12(4) , 261-75, (1993)] |
Antiatherosclerotic actions of isradipine.
1992-01-01 [J. Cardiovasc. Pharmacol. 19 Suppl 3 , S29-31, (1992)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved